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What is already known about this subject -Mycophenolate mofetil (MMF), the most widely used drug in allograft transplantation, is subject to hepatic and intestinal glucuronidation and enterohepatic cycling.
-Diarrhea is its most frequent adverse event leading to non-compliance, treatment interruption and ultimately to an increased rate of acute rejection.
-Cyclosporine reduces the biliary excretion of mycophenolate metabolites, presumably by inhibiting the efflux transporter MRP2 -When combined with MMF, cyclosporine reduces the incidence of diarrhea, suggesting the role played by biliary excretion of mycophenolate glucuronides in this adverse event.
What this study adds
-In a long term cohort of renal transplant patients on MMF, the two factors significantly associated with a reduced incidence of diarrhea were: the comedication with cyclosporine (as opposed to tacrolimus or sirolimus), and the *2 variant allele of the intestinal UGT1A8.
-Polymorphisms in the others UDP-glucuronosyl-transferase and MRP2 were not significant.
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Introduction
Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA), is an immunosuppressive drug widely used in combination therapy with cyclosporine (CsA), tacrolimus (TAC) or sirolimus (SIR) for the prevention or the treatment of acute rejection following kidney, heart and liver allograft transplantation.
The main adverse events (AE) reported for MPA are gastrointestinal (GI) disorders (in particular diarrhea), bone marrow suppression and anemia (1, 2) . MMF would be discontinued in 20% of the patients because of such adverse events (3) . It was first hypothesized that MMF digestive adverse events could be related to MMF dose and/or to MPA plasma levels (4, 5) but this was not confirmed by a further study (6) . Other hypotheses include the possible predisposition of patients to MMF diarrhea in relation to MPA metabolism, and drug-drug interactions. The metabolism of MPA is mainly by conjugation of its phenol group to give the inactive MPA-phenyl-glucuronide (MPAG) (7) which involves UGT1A9, and to a lower extent UGT1A7, 1A8 and 1A10 (8, 9) . The conjugation of MPA carboxylic acid moiety leads to a second glucuronide, namely MPA-acyl-glucuronide (AcMPAG) (10) , which is mainly produced by UGT2B7 in the liver and, to a lower extent, in other tissues including the intestine and the kidneys (8) .
MMF induces a particular type of diarrhea, the exact mechanism of which remains unknown. Several authors reported that the normal villous structure of the small bowel was lost (11) (12) (13) . Owing to the reactivity of AcMPAG (14) , (15) , it was suggested that AcMPAG could be involved in this adverse event through a secondary immunological mechanism (16) . However, neither MPAG nor AcMPAG plasma exposures were associated with diarrhea in a study in kidney transplants patients (6) , where the only significant factor found was the calcineurin inhibitor associated to MMF: a lower inserm-00446912, version 1 -7 Feb 2011
incidence of diarrhea was observed in patients co-treated with CsA than in those cotreated with TAC. As CsA inhibits the Multidrug Resistance Protein 2 (MRP2)-mediated excretion of MPA metabolites into the bile (17) , it suggests that biliary excretion of MPA metabolites, hence intestinal exposure to these metabolites would be more closely linked with diarrhea than systemic exposure.
The aim of this study was to investigate in a long-term cohort of renal transplant patients on MMF the influence on digestive adverse events of: (i) polymorphisms of the genes encoding the UGTs involved in MPA intestinal metabolism (UGT1A7, UGT1A8, UGT1A9 and UGT2B7); (ii) polymorphisms of the gene encoding the efflux transporter involved in the biliary excretion of MPA metabolites (ABCC2); and (iii) coadministered immunosuppressants.
Methods
Patients
The clinical data-on-file and banked DNA samples from patients transplanted between 1996 and 2006, routinely followed as outpatients at Limoges University hospital were retrospectively studied. The ethics committee of Limoges hospital approved the protocol. Informed consent was obtained from each living patient, while the French Health Authorities have waived the requirement for consent for deceased patients. The following inclusion criteria were used: recipient age > 18 years; functioning graft after more than one year posttransplantation; kidney graft from a cadaveric donor;
constitutional DNA available; deceased patient or signed informed consent. Exclusion criteria were as follows: patient age < 18 years, pregnancy, graft survival < 1 year and kidney and pancreas, heart or liver combined transplantation. For each patient, the Genomic DNA bank DNA collection and conservation was performed by the immunogenetic laboratory of Limoges University Hospital. Genomic DNA was extracted from EDTA-treated blood using a previously described manual method (18) . and UGT1A7 assays which required 1.5 min elongation steps and 45 PCR cycles.
Identification of genotypes
Statistical analysis
Deviations from the Hardy-Weinberg equilibrium were studied using the Fisher exact test. The effect of the polymorphisms (SNPs or haplotypes) on phenotypes was investigated using the Cox proportional hazard model, considering successively all GI AEs and diarrhea only. P values less than 0.05 were considered significant and 95%
confidence intervals provided when relevant. For SNP and haplotype association analyses, the most frequent allele was considered as the reference. When the frequency of variant homozygous patients was lower than 5%, these patients were gathered with the heterozygotes. For multivariate analysis, the significance of variables in the final model was tested by a backward stepwise process using the likelihood ratio to evaluate the effect of omitting variables. After studying the effect of each polymorphism independently, the association of haplotypes with GI AEs was analyzed using the THESIAS program (http://genecanvas.ecgene.net) (19) when appropriate.
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The ABCC2 polymorphism was investigated in 2 subgroups of treatment independently:
CsA and TAC /SIR because of the hypothesis of ABCC2 biliary inhibition by CsA.
In order to investigate the effect of MMF dose on the incidence of diarrhea, the dose at the time of the first episode of diarrhea in "case" patients was compared to the dose collected at a similar time after initiation of MMF in "control" patients paired on
follow-up duration while on MMF. Dose was classified into 4 groups (≤750, 1000, 1500
or ≥2000) and compared using the Fisher exact test, then in two groups (<2g or >=2g) to be analyzed using the Cox model. For significant covariates, time-to-event data (first episode) were estimated using Kaplan-Meier analysis for patients with or without the factor of interest, and groups were compared by the log-rank test.
Except when stated otherwise, all statistical analyses were performed using Statview 5.0 (SAS Institute Inc, Cary, NC, USA).
Results
Clinical Data
The clinical and demographic characteristics of the 256 patients who fulfilled the five patients had more than 2 episodes of diarrhea. The mean MMF dose at the time of the episode was 1750±699 g in the group with diarrhea (cases) and 1768±443 g in the group without (controls) (ns). Among patients with diarrhea, there was a significant difference in MMF dose between patients co-treated with TAC (1278±521 mg) and those co-treated with either SIR (1889±333 g) or CsA (1927±738 g) (p=0.0026).
Linkage disequilibrium study
All the genotype distributions were in conformity with the Hardy-Weinberg equilibrium and similar to those reported in the literature (table 1) 
Effects of co-administered immunosuppressant and MMF dose
The percentage of patients with diarrhea was 17.8%, 54.5% and 53.1% in the CsA, SIR and TAC subgroups, respectively (table 2) . There was no difference in the incidence of diarrhea between patients on TAC or SIR (Cox model: p=0.5789) (Fig.1 ).
Consequently, due to the rather small number of patients in these subgroups (n = 49 and 22, respectively), they were combined for comparison to CsA co-treated patients.
Univariate analysis using the Cox model showed a highly significant association of the p<0.0001).
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No significant association was found between GI AEs and MMF dose at the time of the event, whether the dose was considered in four groups (≤750, 1000, 1500, ≥2000;
Fisher exact test p=0.095) (Fig. 2) , or in two groups (<2000 and ≥2000: Hazard Ratio 1.146; CI95% (0.702-1.869); p=0.5861) (table 3) .
Survival analysis
For patients with more than 1 episode of diarrhea, only the first episode was taken into account. Kaplan Meier analysis of the time to the first episode of diarrhea demonstrated a significantly higher incidence in carriers of at least one UGT1A8*2 variant allele ( 
Pharmacogenetic association
Considering again the first episode of diarrhea, univariate analysis showed non-carriers of UGT1A8*2 had a significantly higher incidence of diarrhea than heterozygous or homozygous carriers of the allele (HR=1.968; 95%CI (1.163-3.322); p=0.0117). 
Discussion
Based on the data collected retrospectively in 256 renal transplant patients receiving MMF, we found that patients given tacrolimus or sirolimus or non-carriers of UGT1A8*2 had a higher incidence of diarrhea than those given cyclosporine or carrying the UGT1A8*2 allele, respectively. Several studies investigated the relations between gene polymorphisms of the UGTs or efflux transporters and interindividual variability of MMF exposure, but only a few focused on the direct association of these polymorphisms with MMF-related AEs. Here we studied the potential link of these genes with the occurrence of MMF-related diarrhea episodes. The low numbers of other kinds of AEs prevented us from performing statistical analyses for each of them.
The co-administered calcineurin was also taken into consideration, since cyclosporine is known to influence MMF pharmacokinetics through drug-drug interactions and tacrolimus to induce diarrhea. To the best of our knowledge, this is the first pharmacogenetic study of MMF-related toxicity in a long-term cohort of renal transplant patients. The number of patients studied over this extended period (1996 to 2006) represents a large sample of the renal transplant population in our center.
MMF-related diarrhea was the major digestive AE reported in the patients' files. Before MMF release, it had already been reported that patients under TAC had a higher incidence of diarrhea than patients under CsA: in a multicenter randomized trial comparing TAC versus CsA in association with azathioprine and steroids, the one year incidence of diarrhea was twice as much in TAC patients (21.8% vs 10.3%; p<0.005) (21) . In comparison, the incidence here was higher, at 53.1%, 54.5% and 17.8% for TAC, SIR and CsA, respectively, suggesting that MMF represents an independent risk factor of diarrhea. This study shows that the associated immunosuppressant is the main factor associated with diarrhea in patients on MMF: CsA was associated with approx. a latter. However, there was no difference in the incidence of diarrhea between males and females.
We observed a longer follow up period for patients co-treated with CsA as compared to those co-treated with TAC or SIR, which is due to the fact that cyclosporine was more often prescribed than tacrolimus or sirolimus over the first years of the follow-up period.
The daily dose of MMF itself does not seem to influence the risk of diarrhea, although in clinical practice, a dose decrement is sometimes used to stop or reduce it. The relative risk of the MMF dose, estimated from 121 renal transplants by Borrows et al., was very low (1.17 per 1g-increase of MMF dose) (5) . In this study, we compared the dose received before the adverse events in patients with diarrhea to that of paired patients without. Although the pairing strategy did not allow for more than one control per case, resulting in a loss of statistical power, the effect of MMF dose was not significant in this sub-group of 136 patients, which is consistent with another study where patients who suffered from diarrhea had not received a significantly different MMF daily dose than those who did not (6) . Moreover, we found that patients on tacrolimus had the highest incidence of diarrhea although they received a lower MMF dose at the time of diarrhea than patients on SRL of CsA. The high reactivity of AcMPAG could possibly contribute to MMF GI AEs. Alternatively, the amount of MPA produced in the gut from the hydrolysis of MPAG during MPA enterohepatic cycling could also possibly trigger local inflammation, although MMF is already partly hydrolyzed to MPA in the gut lumen or in intestinal epithelial cells, due to the ubiquity of esterases in the body. In this study we investigated the major polymorphisms of the isoforms thought to be involved in MPA intestinal metabolism or metabolites excretion and found that patients carrying inserm-00446912, version 1 -7 Feb 2011 the UGT1A8*2 allele had a lower risk of diarrhea than homozygous wild-type carriers.
Bernard et al found that UGT1A8 produces both MPAG and AcMPAG using stablyexpressed enzyme in HEK-293 cells. In their study, cells transfected with UGT1A8*2 had a decreased capability to produce AcMPAG as compared to UGT1A8*1 (V max and
Cl int values were divided by 2) but similar activity for MPAG formation (26) . Thus, the lower incidence of MMF-related diarrhea found here in patients carrying the UGT1A8*2 allele could possibly be linked to a lower local production of AcMPAG, which would prevent its toxicity on the intestinal mucosa. The relative risk of diarrhea linked with the co-administered immunosuppressant is greater than that of the UGT1A8
polymorphism, but the UGT activity might be an important factor in CsA treated patients (whose biliary excretion of metabolites is reduced) contrary to patients receiving SIR or TAC, as suggested by the ranking of their combined effects (Fig. 4) .
We observed no effect of UGT1A8*2 when GI AEs were studied as the whole, which included diarrhea, abdominal pain, nausea/vomiting and anorexia. It was already suggested that MMF diarrhea can be due to a local mechanism involving MPA glucuronidation. This hypothesis is probably less likely for the other GI AEs. This can explain why the results were not similar when studying diarrhea alone or together with the other GI AEs. We hypothesized that GI AEs as a whole represented a too heterogeneous phenotype, masking the association between diarrhea and the genotype.
ABCC2 was another good candidate gene in line with our hypothesis, but we did not find any significant effect of its SNPs or haplotype on the risk of diarrhea in the whole population, or when considering separately patients on CsA and patients on TAC/SIR.
This last result shows that this absence of genotypic effect is not due to a masking MPR2 inhibition, which has been reported for CsA (17) but not for TAC or SIR.
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In conclusion, the inhibition of the biliary excretion of MPA metabolites by CsA and the local production of these metabolites depending on the activity of UGT1A8 may be important risk factors of MMF-related diarrhea. The exact mechanisms underlying these findings deserve further investigation. and CsA co-treated /UGT1A8*2 non-carriers (*p=0.03); (ii) CsA co-treated/UGT1A8*2 carriers and TAC or SIR co-treated/UGT1A8*2 carriers or non-carriers ( § p<0.0001);
(iii) CsA co-treated /UGT1A8*2 non-carriers and TAC or SIR co-treated/UGT1A8*2 carriers or non-carriers (# p<0.01). In patients co-treated with TAC or SIR, no significant difference was found between UGT1A8*2 carriers and non-carriers. 
